Today’s pharma regulatory environment is complex, with new approaches in areas including clinical trial design, expedited review pathways, digital tools, and innovative reimbursement programs. These policies offer new opportunities for pharma companies, but staying informed and understanding them is a significant challenge. Since 1939, Pink Sheet has been the leader in providing trusted insights on pharma policy, enabling companies to navigate regulatory developments and anticipate future trends.
Pink Sheet offers global news and expert analysis on pharma policy and regulation, with 60+ journalists providing first-hand coverage of key events. The platform is trusted for its independence, thoroughness, and objectivity, supported by an 80-year track record of excellence. Coverage spans innovator prescription products, biosimilars, generic drugs, and regulatory agencies, identifying cross-cutting implications of policy changes.
The digital platform is user-friendly, responsive on mobile devices, and includes robust search and customizable email alerts. Pink Sheet goes beyond headlines by delivering analysis of next steps, implications, and trends, with actionable insights for businesses.
Key information covered includes:
- Opportunities from new approval pathways and drug development incentive programs.
- Emerging regulatory topics like biomarkers and digital tools.
- New payer requirements from government agencies and private insurers.
- Regulatory agency organization and staffing impacts on drug review processes.
- Legislation affecting agency policies and budgets.
- Post-approval issues, including marketing restrictions and safety surveillance.
- Patent issues and litigation trends.
- Drug approval requirements at US FDA, EMA, and CNMPA, with strategic takeaways from precedent-setting approvals.
- US FDA and EU Performance Trackers, tracing products from submission to approval.
- Drug Review Profiles, providing in-depth insights behind approval decisions.
- Global Guidance Tracker, updating new rules and guidances monthly.
- Special focus areas: manufacturing, reimbursement, market access, and regional coverage.
The platform also offers video, audio, proprietary data sets, precise search filters, and customizable email alerts. Users can ask expert journalists for additional information on news stories, data, and analysis.
跨越行业壁垒CITELINE.COM强大的数字平台超越头条的洞察全新用户友好型数字平台在任何移动设备上都能响应，包括强大的布尔搜索和创建自定义、完全响应式邮件警报的能力。覆盖包括创新处方药、生物类似药和通用名药，以及跨不同监管机构的覆盖范围，使我们能够识别政策的跨领域影响。我们将监管发展与商业影响联系起来。
PLUS独家特色咨询分析师：当您需要更多信息时，请随时向我们专家记者咨询我们的任何新闻报道、数据和分析。• 重点领域：制造业、报销、市场准入和区域覆盖。• 美国食品药品监督管理局和欧盟表现追踪器，这是一个追踪产品从提交到批准的数据资源，并追踪特定监管领域的兴趣点，例如被指定为突破性或PRIME产品的药物。• 药品审评概况，深入了解批准决定背后的关键见解和经验教训。• 全球指导追踪器，每月更新新规则和指导，并提供指向官方文档的链接。版 所有 © 2023 Citeline，一家 Norstella 公司。Pharma Intelligence UK Limited 是一家注册于英格 和威 士、公司 号 13787459 的公司，其注册 公室
行业领先平台的行业领先洞察要了解更多我们能为公司带来的优势，请访问：pink.citeline.com• 专利问题与诉讼趋势。必备信息• 监管机构组织及其人员配备，及其对药物审查过程的影响。• 新兴监管议题，例如生物标志物和数字工具。• 批准后的相关问题，包括市场限制和安全监测。• 政府机构和私营保险公司的新付款要求。• 来自新审批途径和药品研发激励计划的机会。• 美国食品药品监督管理局、欧洲药品管理局和中国国家药品监督管理局等机构的药品批准要求，以及开创性批准的战略要点。• 影响代理政策及预算的立法。位于伦敦 SE1 2AQ 的 More London Riverside。
在任意主题或搜索标准上设置自定义邮件提醒，以便您永远不会错过您最需要了解的信息。大量搜索过滤器允许精确的内容定位，文章和搜索可以一键保存和分享。视频、音频和专有数据集使我们的文章和分析生动起来。
